EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study

Xipeng Tao, Lan Liang, Junjie Xu, Lici Xie, Qing Wen, Xiangdong Zhou, Hu Luo

Journal of Thoracic Disease · 2025-01 · 17 (1) · 278-288

DOI: 10.21037/jtd-24-1403 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thoracic Disease, 2025-01. Verfasst von Xipeng Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Army Medical University, Chongqing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small cell lung cancer (NSCLC) presents the most common type of lung cancer, accounting for 80-85% of cases. Combining immunotherapy with radiotherapy (RT) has emerged as a significant research area in recent years. However, the risk of radiation pneumonitis, especially in lung cancer patients, poses a significant concern. Iodine-125 (I125) seed implantation offers a precise, less invasive alternative, minimizing damage to surrounding lung tissues and reducing side effects. This study aims to evaluate the safety and efficacy of I125 seed implantation combined with immune checkpoint inhibitors (ICIs) and chemotherapy (CT) in treating driver gene-negative NSCLC patients.

Methods

Retrospective analysis of 95 patients with driver gene-negative NSCLC who presented to the First Affiliated Hospital of Army Medical University was conducted. Among them, 33 cases in the observation group were treated with I125 seed implantation combined with CT and ICIs (ICIs + CT + I125), and 62 cases in the control group were treated with extracorporeal RT combined with CT and ICIs (ICIs + CT + RT). The primary observational endpoint was median progression-free survival (mPFS), while the secondary observational endpoints included the 1- and 2-year PFS rate and the incidence of adverse events. Results: mPFS was not reached in the observation group but 11.8 months [95% confidence interval (CI): 9.743-13.857] in the control group, a statistically significant difference (P

Schlagwörter

Stichwörter der Autor:innen

Non-small cell lung cancer (NSCLC)chemotherapy (CT)immune checkpoint inhibitors (ICIs)iodine-125 seed (I125 seed)

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Army Medical University, Chongqing, China.

Zitieren

APA

Tao, X., Liang, L., Xu, J., Xie, L., Wen, Q., Zhou, X., & Luo, H. (2025). Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease, 17(1), 278-288. https://doi.org/10.21037/jtd-24-1403

Vancouver

Tao X, Liang L, Xu J, Xie L, Wen Q, Zhou X, et al. Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease. 2025;17(1):278-288. doi:10.21037/jtd-24-1403

BibTeX
@article{Tao2025,
  author = {Tao, Xipeng and Liang, Lan and Xu, Junjie and Xie, Lici and Wen, Qing and Zhou, Xiangdong and Luo, Hu},
  title = {Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study},
  journal = {Journal of Thoracic Disease},
  year = {2025},
  volume = {17},
  number = {1},
  pages = {278--288},
  doi = {10.21037/jtd-24-1403}
}
Kostenlos starten →